511 reports of this reaction
3.8% of all EPTINEZUMAB JJMR reports
#4 most reported adverse reaction
THERAPEUTIC RESPONSE SHORTENED is the #4 most commonly reported adverse reaction for EPTINEZUMAB JJMR, manufactured by Lundbeck Pharmaceuticals LLC. There are 511 FDA adverse event reports linking EPTINEZUMAB JJMR to THERAPEUTIC RESPONSE SHORTENED. This represents approximately 3.8% of all 13,519 adverse event reports for this drug.
Patients taking EPTINEZUMAB JJMR who experience therapeutic response shortened should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
THERAPEUTIC RESPONSE SHORTENED is moderately reported among EPTINEZUMAB JJMR users, representing a notable but not dominant share of adverse events.
In addition to therapeutic response shortened, the following adverse reactions have been reported for EPTINEZUMAB JJMR:
The following drugs have also been linked to therapeutic response shortened in FDA adverse event reports:
THERAPEUTIC RESPONSE SHORTENED has been reported as an adverse event in 511 FDA reports for EPTINEZUMAB JJMR. This does not prove causation, but indicates an association observed in post-market surveillance data.
THERAPEUTIC RESPONSE SHORTENED accounts for approximately 3.8% of all adverse event reports for EPTINEZUMAB JJMR, making it a notable side effect.
If you experience therapeutic response shortened while taking EPTINEZUMAB JJMR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.